{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:10Z","timestamp":1772165890874,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A systematic examination of low-dose CT (LDCT) scan, beside lung nodules, may disclose the presence of undiagnosed diseases, improving the efficacy and the cost\/efficacy of these programs. The study was aimed at evaluating the association between LDCT scan findings and non-oncologic and oncologic diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The LDCT scan of participants to the \u201cUn Respiro per la vita\u201d\n                      <jats:sup>\u00ae<\/jats:sup>\n                      lung cancer screening program were checked and abnormal findings, beside lung nodules, recorded. First admission to the acute care because of cardiovascular (CD), respiratory (RD) and oncological diseases (OD) in the following three years were retrieved. The association of LDCT scan abnormal findings with CD, RD and OD was assessed through univariable and multivariable logistic regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age of 746 participants was 62\u00a0years (SD:5), 62% were male. 11 (1.5%) received a diagnosis of lung cancer. 16.1% participants were admitted to the acute care in the following three years: 8.6% for CD, 4.3% for RD and 5.2% for OD. Valve calcification (OR 2.02, p:0.02) and mucus plugs (OR 3.37, p:0.04) were positively associated with CD, while sub-pleural fibrosis had a protective role (OR 0.47, p:0.01). Lung nodules\u2009&gt;\u20098\u00a0mm (OR 5.54, p:\u2009&lt;\u20090.01), tracheal deviation (OR 6.04, p:0.01) and mucus plugs (OR 4.00, p:0.04) were positively associated with OD admissions. Centrilobular emphysema OR for RD admissions was 1.97 (p:0.06).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The observed association between selected LDCT findings and ensuing CD, RD and OD suggests that the information potential of LCDT goes beyond the screening of lung cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-022-01826-1","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:04:00Z","timestamp":1643612640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The additional value of lung cancer screening program in identifying unrecognized diseases"],"prefix":"10.1186","volume":"22","author":[{"given":"Panaiotis","family":"Finamore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Tanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-1684","authenticated-orcid":false,"given":"Filippo","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Pedone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Angelici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nera","family":"Agabiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cascini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Beomonte","family":"Zobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele Antonelli","family":"Incalzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfilippo","family":"Crucitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"1826_CR1","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Screening for lung cancer: US preventive services task force recommendation statement. JAMA. 2021;325:962\u201370.","DOI":"10.1001\/jama.2021.1117"},{"key":"1826_CR2","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395\u2013409.","DOI":"10.1056\/NEJMoa1102873"},{"key":"1826_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1164\/rccm.201505-1040OC","volume":"193","author":"MMW Wille","year":"2016","unstructured":"Wille MMW, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193:542\u201351.","journal-title":"Am J Respir Crit Care Med"},{"key":"1826_CR4","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1164\/rccm.201408-1475OC","volume":"191","author":"M Infante","year":"2015","unstructured":"Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191:1166\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"1826_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20400","volume":"20","author":"JK Field","year":"2016","unstructured":"Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess Winch Engl. 2016;20:1\u2013146.","journal-title":"Health Technol Assess Winch Engl"},{"key":"1826_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJMoa1211776","volume":"368","author":"MC Tammem\u00e4gi","year":"2013","unstructured":"Tammem\u00e4gi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728\u201336.","journal-title":"N Engl J Med"},{"key":"1826_CR7","doi-asserted-by":"crossref","unstructured":"Tammem\u00e4gi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11:e1001764.","DOI":"10.1371\/journal.pmed.1001764"},{"key":"1826_CR8","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1001\/jama.2016.6255","volume":"315","author":"HA Katki","year":"2016","unstructured":"Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315:2300\u201311.","journal-title":"JAMA"},{"key":"1826_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/CEJ.0b013e328351e1b6","volume":"21","author":"U Pastorino","year":"2012","unstructured":"Pastorino U, Rossi M, Rosato V, Marchian\u00f2 A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2012;21:308\u201315.","journal-title":"Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP"},{"key":"1826_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S1470-2045(16)30069-9","volume":"17","author":"JE Walter","year":"2016","unstructured":"Walter JE, Heuvelmans MA, de Jong PA, Vliegenthart R, van Ooijen PMA, Peters RB, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol. 2016;17:907\u201316.","journal-title":"Lancet Oncol"},{"key":"1826_CR11","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1164\/rccm.201708-1678ST","volume":"196","author":"PJ Mazzone","year":"2017","unstructured":"Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, et al. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American thoracic society policy statement. Am J Respir Crit Care Med. 2017;196:e15-29.","journal-title":"Am J Respir Crit Care Med"},{"key":"1826_CR12","doi-asserted-by":"crossref","unstructured":"Kauczor H-U, Baird A-M, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, et al. ESR\/ERS statement paper on lung cancer screening. Eur Respir J. 2020;55.","DOI":"10.1183\/13993003.00506-2019"},{"key":"1826_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.201410-1777CI","volume":"191","author":"LT Tanoue","year":"2015","unstructured":"Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Am J Respir Crit Care Med. 2015;191:19\u201333.","journal-title":"Am J Respir Crit Care Med"},{"key":"1826_CR14","doi-asserted-by":"crossref","unstructured":"Rocco R, Incalzi RA, Pennazza G, Santonico M, Pedone C, Bartoli IR, et al. BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes\u2020. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2016;49:1112\u20137; discussion 1117.","DOI":"10.1093\/ejcts\/ezv328"},{"key":"1826_CR15","first-page":"361","volume":"72","author":"G Mangiameli","year":"2017","unstructured":"Mangiameli G, Longo F, Grasso RF, Iacopino A, Rocco R, Quintarelli F, et al. Focus on lung cancer screening program at Campus Bio-Medico of Rome: update on over 3250 patients. Minerva Chir. 2017;72:361\u20133.","journal-title":"Minerva Chir"},{"key":"1826_CR16","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258:243\u201353.","DOI":"10.1148\/radiol.10091808"},{"issue":"68","key":"1826_CR17","first-page":"114","volume":"2016","author":"H Wang","year":"1979","unstructured":"Wang H, Hou L, Kwak D, Fassett J, Xu X, Chen A, et al. Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression. Hypertens Dallas Tex. 1979;2016(68):114\u201322.","journal-title":"Hypertens Dallas Tex"},{"key":"1826_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1513\/pats.200408-039MS","volume":"2","author":"EFM Wouters","year":"2005","unstructured":"Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:26\u201333.","journal-title":"Proc Am Thorac Soc"},{"key":"1826_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/15412550600977544","volume":"3","author":"PMA Calverley","year":"2006","unstructured":"Calverley PMA, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD. 2006;3:233\u201342.","journal-title":"COPD"},{"key":"1826_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet Lond Engl. 2006;368:1005\u201311.","journal-title":"Lancet Lond Engl"},{"key":"1826_CR21","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s40520-020-01681-2","volume":"33","author":"M Conte","year":"2021","unstructured":"Conte M, Petraglia L, Campana P, Gerundo G, Caruso A, Grimaldi MG, et al. The role of inflammation and metabolic risk factors in the pathogenesis of calcific aortic valve stenosis. Aging Clin Exp Res. 2021;33:1765\u201370.","journal-title":"Aging Clin Exp Res"},{"key":"1826_CR22","doi-asserted-by":"crossref","unstructured":"Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health. 2018;15.","DOI":"10.3390\/ijerph15051033"},{"issue":"192","key":"1826_CR23","first-page":"5226","volume":"2014","author":"AA Lugade","year":"1950","unstructured":"Lugade AA, Bogner PN, Thatcher TH, Sime PJ, Phipps RP, Thanavala Y. Cigarette smoke exposure exacerbates lung inflammation and compromises immunity to bacterial infection. J Immunol Baltim Md. 1950;2014(192):5226\u201335.","journal-title":"J Immunol Baltim Md"},{"key":"1826_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1055\/s-0035-1555607","volume":"36","author":"SR Rosenberg","year":"2015","unstructured":"Rosenberg SR, Kalhan R, Mannino DM. Epidemiology of chronic obstructive pulmonary disease: prevalence, morbidity, mortality, and risk factors. Semin Respir Crit Care Med. 2015;36:457\u201369.","journal-title":"Semin Respir Crit Care Med"},{"key":"1826_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1183\/13993003.00359-2016","volume":"48","author":"J Malhotra","year":"2016","unstructured":"Malhotra J, Malvezzi M, Negri E, Vecchia CL, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48:889\u2013902.","journal-title":"Eur Respir J"},{"key":"1826_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137.","journal-title":"Nature"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01826-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01826-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01826-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:06:03Z","timestamp":1643612763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01826-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01826-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-631523\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"19 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Commission of the Campus Bio-Medico University (protocol:34\/15 PAR ComEt CBM). All the study participants provided written informed consent. Data at follow-up were collected by The Department of Epidemiology of the Lazio Regional Health Service, the regional referral centre for epidemiological research, that has full access to anonymized health information systems and Regional Dialysis and Transplant Registry granted by the Regional Council (DGR 152\/2014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the study participants provided written informed consent to participate. This study does not include participants\u2019 images or video and participants\u2019 details are entirely unidentifiable, thus no consent for publication was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors have no financial and non-financial competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}